there are a few minor points where the publication could benefit from further clarity and I have detailed these below.
The discussion in the abstract mentions "equivalence" but this is designed as a non-inferiorty study Primary Endpoint It should be made clear if the primary outcome is a composite measure of two outcomes or a co-primary outcome. I would expect the former as the latter needs to be accounted for in the Power calulation.
Sample size If thee clinical historical performance is 80%, why is the selected sample size comparing 75% to 85% as opposed to 70% versus 80%.
Non-Inferiority Margin Generally "large" NI margins are only accepted as valid when the experimental arm has some other benefit in it"s profile (which in this case may be cost/ease of use). Whilst I don"t think this is an issue, I think it would be worth noting this in the sample size section as a NI margin of 10% will look large to the uninformed reader.
Statistical Methods
The main efficacy parameter comparing the two treatment arms should be stated, (i.e. odds ratio, risk ratio, absolute change in proportions?). Also how will this difference be assessed between treatment groups (Chi-Square test/regression)?
Kaplan Meier curve are used to present survival estimates whereas cumulative incidence plots are used to show incidence over time.
More information should be provided on the bivariate and multivariate logistic regression models. Do we mean multiple responses or multiple explanatory variables or both and how will terms be evaluated in the model Randomisation Whilst sealed envelopes are far from ideal, it may well be that the practical constraints of the study make this the only feasible approach. Still, it may be picked up as a potential source of bias and the protocol would benefit from specifying and Quality Control process -i.e. will there be regular checks to make sure the sequence is being adhered to and that the correct allocations are being given?
REVIEWER
Xiaokui Mo Ohio State University REVIEW RETURNED 03-Jul-2017
GENERAL COMMENTS
This protocol is well designed. The primary and secondary outcomes have been well defined. However, the sample size description is confusing and needs to be revised. The sample size determination has to be based on the two groups comparison (intervention arm vs Soc arm), not as a whole study population (n=395). The author did use two groups at the end, but used superiority method, violating the hypothesis. 
This report is a protocol for a clinical trial aiming to evaluate the realworld effectiveness of an alternative system (Point-of-care testing) for efficiently monitoring ART treatment. It is important because it can help determine whether this model of care is more efficacious and cost-effective than the standard system of delivery of care to stable HIV patients treated with ART in South Africa. This is a critical step toward achieving the UNAIDS 90-90-90 targets.
The authors propose a very timely and important study, which aims to determine whether point-of-care testing combined with chronic care delivery by enrolled nurses can obtain better outcomes in terms of retention in care, virological suppression, and efficiency outcomes. The study design, as well as the primary and secondary outcomes, are clearly described. Table 1 is particularly very helpful in summarizing the study design. The proposed statistical analyses are well-suited for the study. The cost analysis is clearly described.
Criticisms:
The authors do not clearly describe the theoretical or intuitive mechanisms through which POC and/or chronic care delivery by enrolled nursed should lead to better outcomes. It is briefly discussed and buried in the discussion section when it should be used to motivate the study. Secondly, the authors' study design limits the impact of the study. From the proposed design, one cannot distinguish which mechanism of the proposed model of care might enhance outcomes (i.e. POC vs enrolled nurses) compared to the standard of care. Ideally, two additional experimental arms would be added to the study design, so that the independent and interaction effects of these components of the model of care can be assessed. It would also be helpful if the authors provided information on when test results in the SOC model are communicated to the patients (I suspect at the follow-up visit).
For the sample size calculation, the authors should provide the equations and codes for their calculations in an appendix, supported by appropriate references. Table 2 needs to be further explained, and the first column in particular.
I am unable to reproduce the author's sample calculation; I suspect they used the SAS or R suite for the power calculation: ## SAS Code proc power; twosamplefreq groupweights=(1 1) groupps=(0.8 0.9) alpha=0.025 power=0.8 test=PChi sides=1 ntotal=.; plot min=0.1 max=0.9; run; ## R code install.packages("gsDesign"); require("gsDesign"); alpha <-0.025; beta <-0.2; p1 <-0.9; p2 <-0.8; nBinomial(p1=p1, p2=p2, alpha=alpha, beta=beta, delta0=0, ratio=1, sided=1, outtype=1, scale="Difference", n=NULL);
For the statistical analyses, the specific models to be estimated should be included in the protocol (which control variables would be used?). The specific tests that will be conducted on the differences of proportions should also be presented. Readers might also be interested in heterogeneous treatment effects (whether the effects differs by subgroups). In the "Ethics and Dissemination" section the authors should clarify what they mean by "on reasonable request". In the spirit of transparency, we would highly recommend that the authors make their deidentified data and analytical codes available to the public.
REVIEWER

Hui Nian
Vanderbilt University Medical Center, USA REVIEW RETURNED 08-Jul-2017
GENERAL COMMENTS
This study protocol is clearly written. Sample size is properly justified and data analysis plan is well drafted. A couple of minor issues. First, please discuss a little bit about drop out and inadherence to the protocol and how this would be taken into account in the sample size calculation and data analysis. Second, may want to include a multivariable logistic regression analysis for the primary endpoint. Though this is a randomized trial, it's still good to control for confounders.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1.
Comment:
The primary outcomes defined in the protocol are not same as defined in the clinical trials.gov registration. Please clarify if retention in care is primary outcome. (it is not in the registration). Also there are other discrepancy between the registration and this protocol. The information should be accurate in both.
Authors" Reply: Thank you for your comments regarding the clincialtrials.gov registration. We have amended the registration and protocol manuscript to better describe the primary outcome as below: Line 255-258: "The primary outcome is a composite measure of retention in care and virological suppression at 12 months after study enrolment (18 months on ART). Retention in care is defined as collecting ART at the 12-month study visit, while virological suppression is defined as a VL <200 copies/ml using the Roche Taqman® v2.0 (Roche Diagnostics, Basel, Switzerland)".
We have also provided the complete, detailed list of secondary outcomes to the clinicaltrials.gov registration, to fully reflect the study protocol.
Reviewer 2 Comment:
Given the small sample size planned it would be useful to have a statistician review to be certain the study is powered to have enough participants to meet the study objective. This will assure the study design is sufficient to meet the research objectives. Does the study have enough participants to adequately meet the objectives?
Authors" Reply: Thank you for this comment regarding the sample size calculations which was noted by several reviewers. The study has been reviewed by a biostatistician, Dr. Deborah Donnell, the principal investigator for the HIV Prevention Trials Network (HPTN) statistical centre. Her involvement has helped ensure the study is powered to meet the primary objective, as described in response to Reviewer 3.
Comment:
What are the dates the study is expected to start?
Authors" Reply:
We have included the start date of the study in the manuscript as below. Line 361-362: "Enrolment started on 24th February 2017 and is predicted to be completed in August 2017."
Reviewer 3
Comment: Generally this is a well written protocol and gives a good overview of the study to be carried out. Whilst the design of the study is clear, there are a few minor points where the publication could benefit from further clarity and I have detailed these below. Authors" Reply: Many thanks for your detailed review and for recognizing the importance of the work.
Comment:
The discussion in the abstract mentions "equivalence" but this is designed as a non-inferiority study.
We have amended the abstract to include non-inferiority. Line 45-47: "This study aims to demonstrate whether POC VL testing combined with task shifting to enrolled nurses is non-inferior and costeffective compared to laboratory-based VL monitoring and standard HIV care."
Comment: Primary Endpoint. It should be made clear if the primary outcome is a composite measure of two outcomes or a co-primary outcome. I would expect the former as the latter needs to be accounted for in the Power calculation.
Authors" Reply: Thank you for this suggestion, we have clarified the primary outcome as above (response to Reviewer 1).
Comment: Sample size. If the clinical historical performance is 80%, why is the selected sample size comparing 75% to 85% as opposed to 70% versus 80%.
Thank you for your comments regarding the sample size, which was mentioned by several reviewers. We have reviewed our calculations and amended the text and Table 2 to reflect this. Line 377-285: "The sample size and power calculation are based on determining non-inferiority of the intervention arm (Table 2 ). Based on the clinic"s historical performance, 80% of adults in the standard of care arm will be virologically suppressed and retained at 12 months. With a non-inferiority margin of -10%, which would be acceptable if the intervention is less costly, a trial of 198 participants per arm will have 80% power with the lower limit of a one-sided 95% confidence interval to declare non-inferiority." Comment: Non-Inferiority Margin. Generally "large" NI margins are only accepted as valid when the experimental arm has some other benefit in its profile (which in this case may be cost/ease of use). Whilst I don"t think this is an issue, I think it would be worth noting this in the sample size section as a NI margin of 10% will look large to the uninformed reader.
We have clarified this in Lines 279-280 (see above).
Comment: Statistical Methods. The main efficacy parameter comparing the two treatment arms should be stated, (i.e. odds ratio, risk ratio, absolute change in proportions?). Also how will this difference be assessed between treatment groups (Chi-Square test/regression)? Kaplan Meier curve are used to present survival estimates whereas cumulative incidence plots are used to show incidence over time.
Authors" Reply: Thank you for this comment. We will not use Kaplan Meier estimates to assess the primary outcome as virological suppression is only being assessed at study exit. We have modified the statistical methods as below. Line 310-315: "The primary analysis will estimate the absolute difference in proportions achieving the primary outcome between the intervention and control arms, assessed using the χ2 test. For binary secondary outcomes, the absolute difference in proportions will be assessed using the χ2 test. For continuous secondary outcomes, means in each arm will be compared using the unpaired t test."
Comment: More information should be provided on the bivariate and multivariate logistic regression models. Do we mean multiple responses or multiple explanatory variables or both and how will terms be evaluated in the model?
Authors" Reply: Thank you for this comment. We have clarified the text below. Line 315-318: "We will perform bivariate and multivariable logistic regression to identify independent risk factors for reaching the primary outcome. Each covariate will be assessed for statistical significance in a bivariate logistic regression. All terms with nominal statistical significance at P <0.05 will be assessed in a multivariable regression."
Comment: Randomisation. Whilst sealed envelopes are far from ideal, it may well be that the practical constraints of the study make this the only feasible approach. Still, it may be picked up as a potential source of bias and the protocol would benefit from specifying the Quality Control process -i.e. will there be regular checks to make sure the sequence is being adhered to and that the correct allocations are being given?
Authors" Reply: Thank you for this comment. We have described the checks in place below. : "To ensure the allocation sequence is followed, study nurses performing enrolment procedures will not open randomization envelopes; this will be performed by the study co-ordinator, with subsequent checks to verify correct allocation."
Reviewer 4:
Comment: This protocol is well designed. The primary and secondary outcomes have been well defined.
Authors" Reply: Many thanks for your review and comments Comment: However, the sample size description is confusing and needs to be revised. The sample size determination has to be based on the two groups comparison (intervention arm vs Soc arm), not as a whole study population (n=395). The author did use two groups at the end, but used superiority method, violating the hypothesis. Table 2 has to be revised accordingly. Author's reply: Thank you for these comments which were mentioned by several reviewers. We have described the clarification to the sample size and non-inferiority design in our response to Reviewer 3 above.
Reviewer 4: In addition, the statistics analysis needs more details (e.g. t-test, or other statistics modeling, COX regression).
We have added these details above, in response to Reviewer 3.
Reviewer 5
Comment: This report is a protocol for a clinical trial aiming to evaluate the real-world effectiveness of an alternative system (Point-of-care testing) for efficiently monitoring ART treatment. It is important because it can help determine whether this model of care is more efficacious and cost-effective than the standard system of delivery of care to stable HIV patients treated with ART in South Africa. This is a critical step toward achieving the UNAIDS 90-90-90 targets. The authors propose a very timely and important study, which aims to determine whether point-of-care testing combined with chronic care delivery by enrolled nurses can obtain better outcomes in terms of retention in care, virological suppression, and efficiency outcomes. The study design, as well as the primary and secondary outcomes, are clearly described. Table 1 is particularly very helpful in summarizing the study design. The proposed statistical analyses are well-suited for the study. The cost analysis is clearly described.
Authors" Reply: Many thanks for recognizing the importance of the work and your detailed suggestions and comments.
Comment:
The authors do not clearly describe the theoretical or intuitive mechanisms through which POC and/or chronic care delivery by enrolled nursed should lead to better outcomes. It is briefly discussed and buried in the discussion section when it should be used to motivate the study.
Authors" Reply: Thank you for this comment. We have modified the manuscript, adding the below sections to the introduction, to more clearly state the mechanisms by which POC VL testing and enrolled nurses may influence outcomes and be cost effective. Line 116-123: "There is growing interest in point-of-care (POC) VL assays, which could alleviate the burden on central laboratory services and improve clinical management by providing test results while the patient is still at the clinic, thereby removing the need for specimen transport and follow-up visits. Comment: Secondly, the authors' study design limits the impact of the study. From the proposed design, one cannot distinguish which mechanism of the proposed model of care might enhance outcomes (i.e. POC vs enrolled nurses) compared to the standard of care. Ideally, two additional experimental arms would be added to the study design, so that the independent and interaction effects of these components of the model of care can be assessed Authors" Reply: Thank you for this comment. Unfortunately, within our resources we are unable to modify the trial design to incorporate the reviewer"s suggestion: in addition, the study is already underway. However, we have made the following amendment to the cost-effectiveness section. Line 338-343: "The microcosting data, time and motion studies, and clinical outcomes will be used to estimate the average cost per HIV-positive patient achieving viral suppression and retained in care in the intervention arm compared to standard of care. Furthermore, this data will allow process evaluation of the mechanism by which the different components of the intervention (POC testing and enrolled nurses) contribute the achievement of study outcomes, including costs saved and incurred." For the sample size calculation, the authors should provide the equations and codes for their calculations in an appendix, supported by appropriate references. Table 2 needs to be further explained, and the first column in particular. I am unable to reproduce the author's sample calculation; I suspect they used the SAS or R suite for the power calculation.
We are very grateful to Reviewer 3 for this important comment and detailed review of our sample size calculations. The reviewer has correctly noted that the sample size calculations were incorrect. They have been recomputed, and we have amended the text and Table 2 to reflect this (see above in our response to Reviewer 3). These sample sizes can be replicated in available on-line non-inferiority sample size calculators, e.g. https://www2.ccrb.cuhk.edu.hk/stat/proportion/tspp_sup.htm
Comment:
For the statistical analyses, the specific models to be estimated should be included in the protocol (which control variables would be used?). The specific tests that will be conducted on the differences of proportions should also be presented. Readers might also be interested in heterogeneous treatment effects (whether the effects differs by subgroups).
Author's reply: These changes to the statistical methods and sample size calculations have been detailed above, in our response to Reviewer 3.
In the "Ethics and Dissemination" section the authors should clarify what they mean by "on reasonable request". In the spirit of transparency, we would highly recommend that the authors make their deidentified data and analytical codes available to the public.
Author's reply: Thank you for this suggestion, we have amended this section as below. Line 439-441: "De-identified individual participant data for all outcome measures will be made available after study completion."
Reviewer 6:
This study protocol is clearly written. Sample size is properly justified and data analysis plan is well drafted. A couple of minor issues.
Authors" Reply: Many thanks for your review and comments.
Comment: First, please discuss a little bit about drop out and inadherence to the protocol and how this would be taken into account in the sample size calculation and data analysis.
The primary outcome for this study is both retention in care and viral load suppression. Therefore, loss to follow up in either arm will be captured in the analysis of the primary outcome. Participants who die or migrate out of study follow up will be censored from the primary analysis. However, we predict this to be minimal as eligibility criteria select for patients who are clinically well and plan to remain in the area throughout follow up. Furthermore, follow up time is short. We will perform intention to treat analysis, with a per protocol sensitivity analysis, in the unlikely event that any participants cross over between arms.
